Edition:
United Kingdom

Cellular Biomedicine Group Inc (CBMG.OQ)

CBMG.OQ on NASDAQ Stock Exchange Global Market

10.50USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$10.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
7,210
52-wk High
$13.75
52-wk Low
$5.15

Latest Key Developments (Source: Significant Developments)

Cellular Biomedicine Group reports qtrly ‍loss per share $0.43
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Cellular Biomedicine Group Inc :Cellular Biomedicine Group reports third quarter financial results and recent operational highlights.Cellular Biomedicine Group Inc- ‍$16.3 million cash and cash equivalents as of September 30, 2017 as compared to $27.3 million as of June 30, 2017​.Cellular Biomedicine Group Inc - Qtrly ‍loss per share $0.43​.Cellular Biomedicine Group Inc - Qtrly net sales and revenue $106,787 versus $10,012‍​.  Full Article

Thermo Fisher Scientific and Cellular Biomedicine announce partnership to develop manufacturing processes
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Cellular Biomedicine Group Inc :Thermo Fisher Scientific and Cellular Biomedicine Group announce strategic partnership to develop manufacturing processes.Cellular Biomedicine Group Inc - ‍partnership focuses on research and development of an automated cell therapy manufacturing system​.  Full Article

Cellular Biomedicine Group announces resale of up to 5.1 mln shares of common stock for sale by selling stockholders
Monday, 20 Jun 2016 

Cellular Biomedicine Group Inc :Resale of up to 5.1 million shares of common stock for sale by the selling stockholders - SEC filing.  Full Article

Cellular Biomedicine reports Q1 results
Monday, 9 May 2016 

Cellular Biomedicine Group Inc : Cellular Biomedicine Group Inc says cash and cash equivalents as of march 31, 2016 were $15.7 million compared to $14.9 million as of december 31, 2015 . Cellular biomedicine group reports first quarter 2016 financial results and provides business highlights .Q1 revenue $488,500 versus $603,400.  Full Article

Cellular Biomedicine Group Inc announces positive 48-week data from phase IIb Clinical Trial for Knee Osteoarthritis Stem Cell ReJoin Therapy
Wednesday, 13 Jan 2016 

Cellular Biomedicine Group Inc:Announces positive 48-week data from phase IIb Clinical Trial for Knee Osteoarthritis Stem Cell ReJoin Therapy.Says no serious adverse events reported to date.Says 48-week end of study shows primary,secondary endpoints of rejoin therapy group having improved significantly compared to baseline.Says total womac scores as a primary end point show statistical treatment significance at week 48 compared to the baseline.  Full Article

Cellular Biomedicine Group Inc says Wei Cao will not seek renewal of employment contract as CEO
Monday, 11 Jan 2016 

Cellular Biomedicine Group Inc:Says Wei Cao will not seek renewal of employment contract as CEO.Says committee of board has been established to oversee the professional recruitment of a new chief executive officer.Tony Liu, will assume full responsibilities as the interim chief executive officer.  Full Article

BRIEF-Cellular Biomedicine Group reports qtrly ‍loss per share $0.43

* Cellular Biomedicine Group reports third quarter financial results and recent operational highlights